Subscribe

What are you looking for?

Main Menu

明報新聞網

復星醫藥與九源基因達多款生物藥及創新藥械產品海外獨家商業化協議

Future Wealths
Future Wealths
29 5 月, 2025
One Min Read
15 Views
0 Comments
復星醫藥（2196）宣布，與九源基因（2566）就多款生物藥及創新藥械產品達成海外獨家商業化權益合作，復藥將獲得九源基因的獨家授權，就司美格魯肽、骨優導和JY-23等產品，在中東北非、撒哈拉以南非洲全部國家及部分東盟國家的獨家臨床開發、註冊、生產和商業化權益。

原文: https://finance.mingpao.com/fin/instantf/20250529/1748492807952/%e5%be%a9%e6%98%9f%e9%86%ab%e8%97%a5%e8%88%87%e4%b9%9d%e6%ba%90%e5%9f%ba%e5%9b%a0%e9%81%94%e5%a4%9a%e6%ac%be%e7%94%9f%e7%89%a9%e8%97%a5%e5%8f%8a%e5%89%b5%e6%96%b0%e8%97%a5%e6%a2%b0%e7%94%a2%e5%93%81%e6%b5%b7%e5%a4%96%e7%8d%a8%e5%ae%b6%e5%95%86%e6%a5%ad%e5%8c%96%e5%8d%94%e8%ad%b0

Last Update: 29 5 月, 2025

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept